SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: seminole who wrote (1093)8/18/1998 6:15:00 PM
From: David Cathcart  Read Replies (1) of 1826
 
Richard,

I just had a conversation with Lori Weiman. A few interesting comments:

* Both phase I trials for MGI 114 are still ongoing. While they have realized the MTD of MGI 114, and thus they have begun phase II, several patients are still being treated in phase I so they cannot conclude a trial while the patients are still in the program. One patient with pancreatic cancer is in his fourth month of treatment. Other patients, one with head & neck, have shown signs of efficacy. She said the fact that the phase I trials are still ongoing is bitter-sweet. It is good that some patients are apparently benefiting from the drug and thus remain in the trial. The fact that the patients remain though prevents MGI from concluding the trial and compiling and publishing the results. As a PR person, she wants that information to distribute.

* The NCI just posted their MGI 114 trials on their web-site last Friday. The NCI does not advise MGI Pharma of when they are going to post the trials and begin enrolling patients in a given trial. Additional trails will be posted in the near future, but the best way to find out about them is to continue to check the NCI web-site.

* Very positive negotiations are in progress for the Euro deal. Lori was very careful in what she said but the optimism was evident.

* They have been working on a web-site for sometime. One issue holding it up is that they are working out details with the FDA about exactly what can be said about certain drugs (i.e. Salagen for Sjogren's). At this point you can only see the cover page:

mgipharma.com

Volume has slowed to a crawl with MOGN, but I'm not worried. Good things are in store.

Let's shrink some tumors!!!

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News